Navigation Links
Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
Date:11/10/2008

Company Will Host a Conference Call Today To Discuss the Data and Ongoing

Clinical Development Programs

RICHMOND, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today top-line data from its SB-509-601 clinical trial, one of Sangamo's three Phase 2 clinical studies from its ZFP Therapeutic(TM) program to develop SB-509 for diabetic neuropathy (DN). The data demonstrate that repeat administration of the drug is well tolerated in subjects with mild to moderate DN. However, no significant differences were observed between the SB-509 and placebo treated subjects in a number of measures of nerve function and health at the primary analysis point, day 180 post-treatment.

Sangamo management will host a conference call at 5:00 p.m. ET today to review these data and the ongoing clinical studies supporting the development of SB-509.

"Our first Phase 2 study, SB-509-601, had three goals," stated Dale Ando, M.D., Sangamo's vice president, therapeutic development and CMO. "First, we wanted to determine the safety of repeat dosing. Second, we evaluated dose schedule, specifically whether a regimen of three administrations of the maximum dose given at two month intervals would be more effective than a single administration. Finally, we hoped to gain clarity around clinical endpoints for use in the design of future studies. While this study has not added to our data around the most suitable end-points or dosing schedule for a Phase 3 trial, it has demonstrated that the drug continues to have an excellent safety profile. This is valuable information for our future development efforts."

"We also know that SB-509 is an active agent. We have positive preclinical dat
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
2. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
5. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
6. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
7. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
8. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
9. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
10. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
11. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
(Date:8/28/2014)... Washington, USA (PRWEB) August 27, 2014 ... next month for SPIE Laser Damage 2014 ... optical materials for high-power lasers will run 14-17 September. ... society for optics and photonics . , The premier ... for understanding laser damage to optical materials will engage ...
(Date:8/28/2014)... 2014 Supplementing their complete line ... for Eppendorf Safe Lock Centrifuge Tubes . ... highest quality tubes at an affordable price. Eppendorf ... doing chemical, medical, pharmaceutical, and life science research ... regularly able to afford Eppendorf products. , Eppendorf ...
(Date:8/27/2014)... , Aug. 27, 2014 Rhythm, a biopharmaceutical ... genetic deficiencies that result in metabolic disorders, announced today ... S-1 with the U.S. Securities and Exchange Commission (SEC) ... of its common stock. The number of shares to ... have not yet been determined. Citigroup and ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, ... are as follows:   , , , ... , Time:  8:30am Pacific Time , ... Location: The Ritz-Carlton, San Francisco , , , ...
... , PRINCETON, N.J. , May 10 ... the Company), a late-stage biotechnology company, announced today that ... of Treating Inflammatory Disorders of the Gastrointestinal Tract using ... the use of topically active corticosteroids in orally administered ...
... ... its revolutionary Trusted LASIK Surgeons directory service and website at www.TrustedLASIKSurgeons.com ... their vision and find a highly qualified eye surgeon who can help ... LASIK Surgeons directory apart is a unique screening process ensuring that only ...
Cached Biology Technology:Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference 2Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders 2Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders 3Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders 4Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders 5Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 2Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 3Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 4Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 5Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 6Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 7Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 8Baltimore Eye Surgeon Dr. Anthony Kameen Joins Select Group of LASIK & Cataract Surgery Doctors at Trusted LASIK Surgeons 9
(Date:8/29/2014)... in German . ... natural nitrogen cycle on Earth and in biological wastewater ... to depend on nitrite as their source of energy. ... a microbiologist at the University of Vienna, has now ... alternative source of energy. The oxidation of hydrogen with ...
(Date:8/29/2014)... In a cell,s nucleus, chromosomal DNA is tightly ... amalgam biologists call chromatin. Until about two decades ... the mere packing material around which the glamorous ... developed a greater appreciation for how DNA/histone interactions ... multiple research institutions studying the sequence of the ...
(Date:8/28/2014)... free mobile app called TX Invasives is now available ... University of Texas at Austin for identifying harmful non-native ... Invasive species in the United States cause about $137 ... destroy agricultural crops, clog waterways, kill native plants and ... Invasives app for reporting where invasive species occur, we,re ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Mobile app makes ID of harmful plants, insects in Texas a snap 2
... ( T. gondii ) is considered as one of the ... wide range of intermediate hosts, including all mammals and birds. ... and 20% in the world are chronically infected. ... now accepting applications for its Investigative Workshop, Modeling Toxoplasma ...
... have identified a gene they say is a strong ... other maladies associated with the natural flux in hormones ... in the Proceedings of the National Academy of ... showing that a common human variant of the gene ...
... , Feb. 9 Pacific Biomarkers, Inc. (OTC ... support pharmaceutical and laboratory diagnostic manufacturers in the conduct of ... investor conference call for 11:15 a.m. EST ( ... to review the Company,s operating results for the second ...
Cached Biology News:Modeling Toxoplasma focus of workshop 2Research identifies gene with likely role in premenstrual disorder 2Research identifies gene with likely role in premenstrual disorder 3Pacific Biomarkers, Inc. Schedules Second Quarter Conference Call for Friday, February 12, 2010 2
... cells (BTI-TN-5B1-4) derived from Trichoplusia ni ... to be capable of expressing significantly ... compared to other insect cells. High ... doubling time as adherent cultures- Quick adaptation ...
... steadylite plus assay system offers ... sensitivity, Designed for batch-processing systems, ... higher density microplates such as ... free, Convenient storage conditions ( ...
... lysis buffer, PCR mix, DNA polymerase and ... volume PCR reactions. This system can detect ... rod and coccus bacteria, such as Escherichia ... Streptococcus Agalactiae, and etc. With the powerful ...
... Kit is uniquely formulated to give ... protein modification for optimal mass spectrometry ... with traditional silver stains are eliminated ... reagents used do not modify protein ...
Biology Products: